Lantus (Insulin Glargine) More Effective Than Standard Care in Diabetic Patients
Glycemic control maintained for 5 years in pivotal study (Oct. 5)
According to an October 5 announcement from Sanofi, new results from the landmark ORIGIN (Outcome Reduction with Initial Glargine INtervention) trial have shown that treatment with Lantus (insulin glargine) was approximately three-fold more likely (P < 0.001) to achieve and maintain target glycemic levels — defined as hemoglobin A1c (HbA1c) levels of less than 6.5% — versus standard care in patients with pre-diabetes or early type 2 diabetes at high cardiovascular (CV) risk.
In data presented at the European Association for the Study of Diabetes (EASD) 48th Annual Meeting, the use of insulin glargine was an independent predictor of maintaining mean yearly HbA1c levels at less than 6.5% target over 5 years versus standard care.
ORIGIN was a 6-year randomized clinical trial designed to assess the effects of treatment with insulin glargine versus standard care on CV outcomes. The study involved more than 12,500 participants worldwide with pre-diabetes (impaired fasting glycemia or impaired glucose tolerance) or early type 2 diabetes (treated with no more than one oral anti-diabetic agent) and high CV risk. Key results reported in June 2012 at the American Diabetes Association Congress showed that insulin glargine had a neutral effect on CV outcomes but significantly reduced progression from pre-diabetes to diabetes (a secondary outcome) by 28% (P = 0.006).
In the new study, insulin glargine was more effective than standard care at maintaining glycemic control in all subgroups assessed, including age, alcohol consumption, depression, baseline HbA1c, urine albumin:creatinine ratio (ACR), and especially individuals with abdominal obesity (P = 0.011).
For more information, visit the Sanofi Web site.